Healthcare
Live Price
Offline$0.0002
+0.00% today
1Y Change
-80.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viveve Medical, Inc. (VIVE) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 80.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +17.3%, EPS growth of +84.0%, a dividend yield of 0.0%. What stands out right now is revenue +17.3%, EPS +84.0%, free cash flow +16.7% with operating margin -335.4% and ROIC -99.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VIVE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIVE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIVE Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VIVE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.4M
+17.3% YoY
FY Net Income
-$22.0M
-0.5% YoY
Free Cash Flow
-$13.3M
+16.7% YoY
Revenue Growth
+17.3%
EPS Growth
+84.0%
Gross Margin
9.6%
Net Margin
-342.8%
Income statement
USD
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 15M | 19M | 7M | 5M | 6M |
| Gross Profit | 7M | 7M | 1M | 296K | 620K |
| Operating Income | -34M | -45M | -30M | -18M | -22M |
| EBITDA | -33M | -44M | -29M | -17M | -21M |
| Net Income | -37M | -50M | -43M | -22M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 30M | 13M | 7M | 19M |
| Total Assets | 36M | 47M | 27M | 17M | 26M |
| Total Liabilities | 39M | 42M | 10M | 10M | 11M |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 29M | 31M | 4M | 6M | 5M |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2022 Full Year
Operating Cash Flow
13M
+12.6% YoY
Capital Expenditures
—
Free Cash Flow
13M
+16.7% YoY
Key ratios
Gross Margin
9.6%
Operating Margin
-335.4%
Net Margin
-342.8%
ROE
-199.9%
Debt / Equity
0.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.